Yahoo! Finance: Biotechnology Industry News: ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig® (Ponatinib)

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig® (Ponatinib) Jun 1st 2013, 13:00 [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced results of evaluation of the cardiovascular risk profile of Philadelphia-positive leukemia patients treated with Iclusig® in the pivotal PACE trial.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions